Aldeyra Therapeutics is a biotechnology company engaged in developing and commercializing medicines for patients with immune-mediated diseases. The company's primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. The company has additional product candidates in development for proliferative vitreoretinopathy and other retinal diseases, autoimmune disease, and cancer. The company has discovered and are developing two additional reactive aldehyde species inhibitors, ADX-103 and ADX-629, for the treatment of retinal disease and autoimmune disease, respectively.

Celsius Holdings is engaged in the development, marketing, sale and distribution of functional calorie-burning fitness beverages under the Celsius? brand name. Celsius? burns calories by increasing a consumer's resting metabolism and provides energy. Celsius? uses ingredients and supplements such as green tea, ginger, calcium, chromium, B vitamins and vitamin C. The company also sells a powdered form of the active ingredients in its beverages in individual On-The-Go packets as well as several serving canisters. In addition, the company has a second line in its product portfolio, trainer's grade Celsius Heat?. Celsius Heat? is also a dietary supplement.

Chemours is a provider of performance chemicals. The company has three reportable segments: Fluoroproducts, Chemical Solutions, and Titanium Technologies. The company's Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. The company's Chemical Solutions segment is a North American provider of industrial chemicals used in gold production, industrial, and consumer applications. The company's Titanium Technologies segment is a provider of titanium dioxide pigment, a white pigment used to deliver whiteness, brightness, opacity, and protection in a variety of applications.

Cognizant Technology Solutions is a services company, transforming customers' business, operating and technology models for the digital era. The company's services include digital services and solutions, consulting, application development, systems integration, application testing, application maintenance, infrastructure services and business process services. Additionally, the company develops, licenses, implements and supports proprietary and third-party software products and platforms. The company has organized its services and solutions into four practice areas: Digital Business, Digital Operations, Digital Systems and Technology and Consulting.

Harvard Bioscience is a developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company's product families are: Cellular and Molecular Technologies, which includes products designed primarily to support the discovery phase of new drug development; and Pre-Clinical, which provides a preclinical platform to assess physiological data for basic research, drug discovery, drug development services, and services for monitoring physiological parameters of animal models used in biomedical research.

Organogenesis Holdings is a regenerative medicine company focused on the development, manufacture and commercialization of solutions. The company's Advanced Wound Care products include Apligraf for the treatment of VLUs and DFUs; Dermagraft for the treatment of DFUs; PuraPly Antimicrobial (PuraPly AM) to address biofilm across various wound types; and Affinity and NuShield to address various wound sizes and types. The company's Surgical and Sports Medicine products include ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical application in targeted soft tissue repairs; and PuraPly AM for surgical treatment of open wounds.

PBF Energy is a holding company. Through its subsidiaries, the company is engaged as an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants and other petroleum products in the U.S. The company operates in two business segments: refining, which the company produces a variety of products at each of its refineries such as gasoline, ultra-low-sulfur diesel, heating oil, jet fuel, lubricants, petrochemicals and asphalt; and logistics, which through its PBF Logistics LP subsidiary, the company owns or leases, operates, develops and acquires crude oil and refined petroleum products terminals, pipelines, storage facilities and similar logistics assets.

Penn Virginia is an independent oil and gas company engaged in the onshore exploration, development and production of crude oil, natural gas liquids (NGLs) and natural gas. The company's operations consist primarily of drilling unconventional horizontal development wells and operating its producing wells in the Eagle Ford Shale, in Gonzales, Lavaca, Fayette and DeWitt Counties in South Texas. The company operates in one segment, which is the exploration, development and production of crude oil, NGLs and natural gas. The company sells its oil, NGL and natural gas products using short-term floating price physical and spot market contracts.

Safestore Holdings is engaged in the rental of self-storage space and the sale of ancillary products such as insurance and merchandise (for example, packing materials and padlocks) in both the U.K. and Paris.

Vapotherm is a medical technology company focused on the development and commercialization of its proprietary Hi-VNI Technology products that are used to treat patients of all ages suffering from respiratory distress. The company's Hi-VNI Technology delivers non-invasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a small-bore nasal interface. The company provides four versions of its Precision Flow systems: Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. The company's companion products include: Vapotherm Transfer Unit 2.0, the Q50 compressor, the aerosol aeroneb adaptor, and a tracheostomy adaptor.